Effect Of Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers On the Clinical Outcome In COVID-19 Patients With Hypertension

2Department of Infectious Diseases, School of Medicine, Infectious and Tropical Diseases Research Center, Health Research Institute, Razi Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Journal of Cellular & Molecular Anesthesia:Vol. 6, issue 4; e149739

Published online:Oct 19, 2021

Article type:Original Articles

How to Cite:Zahra Fakhrae Saeid BitarafRoohangize NashibiFatemeh AhmadiSafoura Khosravi Shokrollah Salmanzadehet al.Effect Of Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers On the Clinical Outcome In COVID-19 Patients With Hypertension.J Cell Mol Anesth.6(4):e149739.https://doi.org/10.22037/jcma.v6i4.35596.

Abstract

Background: Hypertension is the main factor to predict the severity and mortality of COVID-19. The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is challenging. This study aimed to investigate the effect of ACEIs and ARBs on clinical outcomes in COVID-19 patients with hypertension. Materials and Methods: This cross-sectional study was carried out on 498 patients who were referred to Razi hospital following COVID-19 development and also had hypertension. Patients were divided into two groups receiving drugs in the ACEIs and ARB's groups and those not receiving these drugs. The primary outcome was death up to one month after the onset of symptoms. Results: Cardiovascular disease in patients taking ACEIs/ARBs was higher (p<0.001). One hundred eleven deaths (22.3%) were seen in the studied patients in whom 66 deaths (59.5%) belonged to the group not taking ACEIs and ARBs (p>0.05). Seventy-nine patients (15.86%) were admitted to ICU in which 62.03% of these patients died while the non-ICU mortality rate was 14.8% (Odds Ratio = 9.40; 95% CI: 5.54 to 15.95, p <0.001). A subgroup analysis found that among patients with diabetes who had hypertension, the incidence of death was 43.55% in the group taking ARBs/ACEi lower than in another group significant (p = 0.021). Conclusion: The mortality rate in the patients taking ACEIs/ARBs is not different from other groups. It was found that among COVID-19 patients with diabetes who had hypertension, the incidence of death in the patients taking ARBs/ACEi was lower than in another group.

Keywords

COVID-19

SARS-CoV2

angiotensin-converting enzyme inhibitors

angiotensin receptor blockers

ARBs

ACEi

References

1.
References are in the PDF file of the article.

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

CrossRef 0

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Zahra Fakhrae :[PubMed][Scholar]
Saeid Bitaraf:[PubMed][Scholar]
Roohangize Nashibi:[PubMed][Scholar]
Fatemeh Ahmadi:[PubMed][Scholar]
Safoura Khosravi :[PubMed][Scholar]
Shokrollah Salmanzadeh:[PubMed][Scholar]